anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Stroke is a leading cause of disability. Most stroke survivors are discharged home after hospitalization and receive care from informal caregivers (e.g., unpaid spouses) who are often unprepared for the role. Stroke survivorship is an exemplar of a chronic condition that detracts from the affected individual and caregiver's capacity to live well within the home (e.g., psychosocial distress). Early identification of psychosocial distress is likely to lead to timely interventions and, subsequently, decreases in associated morbidity, mortality, and disability. Yet, only a minority of survivors are properly identified and treated for psychosocial distress, and caregivers are primarily forgotten. In-home, objective measures to identify psychosocial distress are lacking. Using facial expression and body motion technology by extracting facial characteristics and body joints (skeletal graph) known to be associated with psychosocial distress (e.g., frowning) provides new opportunities to support in-home telemonitoring. To accommodate real-world, post-stroke home environments, the technology needs to be customized to an in-home environment. Toward this end, the investigators must consider background variability, possible occlusions, privacy concerns, and stroke survivor motor weaknesses, gait impairments, and facial paralysis. Objectives: The primary objectives are to customize facial expression and body motion technology and examine the acceptability of the technology through a study of 6 stroke survivor-informal caregiver dyads within a simulated home environment. The project will serve as a necessary step to amass critical information to design future trials using facial expression and body motion technology. The ultimate goal is to improve psychosocial well-being for those aging at home.
PROBLEM TO BE SOLVED: To improve freshness and neatness of a perfume and maintain them for a long period of time without abundant use of materials having a relatively low vapor pressure by incorporating compounds such as 1-methoxy-2-propanol, 2-methoxy-1-propanol or the like. SOLUTION: This perfume quality-improving agent comprises a compound represented by formula I or formula II (wherein R1 and R2 are each a 1-3C alkyl, 1-10C alkenyl or 6-20C aromatic group). As the 1-3C alkyl groups are cited methyl, ethyl and propyl. As the 1-10C alkenyl group is preferable a vinyl group. As the 6-20C aromatic groups are preferable phenyl and benzyl groups. As R1 and R2 are particularly preferable 1-3C alkyl groups. As the perfume quality-improving agent is employed at least one selected among compounds of formulae I and II. The amount incorporated into a mixed perfume is preferably not more than 50 wt.%, 5-30 wt.% in particular.
The present invention provides are a gold nanoflower structure and a preparation method therefor. The gold nanoflower structure is a gold nanoflower particle, with round-head columns being uniformly distributed at the periphery thereof, obtained by using gold octahedrons, gold balls or gold tetrahedrons as seed crystals and reducing chloroauric acid by using weak reductant in an environment of high-concentration polyvinylpyrrolidone. In addition, also provided in the present invention are a gold nanoflower/quantum dot composite probe for living cell immunofluorescent labeling and photothermal therapy, a preparation method therefor and a use thereof. In comparison with traditional probes, the probe, incorporates the features of photothermal therapy and fluorescent labeling, and is capable of killing cancer cells in an effective and directional way. Two light sources are adopted to bring a tremendous photothermal conversion efficiency and a greater enhancement on fluorescence intensity of quantum dots respectively, thus mutual interference of two effects are avoided tactfully. The coating of silicon dioxide averts the biotoxicity of the gold nanoflower and the quantum dot effectually, enabling the surface of the composite probe to be easily functionalized and also imparting an extraordinarily excellent biocompatibility to the composite probe.
Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-?B activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-?B activity without a second delayed increase in NF-?B activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated Massilia bacterium or population thereof capable of producing a HIV-1 reactivating factor (HRF). Also provided are methods of culturing the Massilia bacteria. Further provided are methods of reactivating a latent Human Immunodeficiency Virus-1 (HIV-1) infection in a subject comprising administering to the subject a HIV-1 reactivating factor produced by Massilia bacteria, optionally with a priming agent.
Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
The specification describes bioconjugates which comprise a bioactive agent and an organocobalt complex. The bioactive agent is covalently bonded directly or indirectly to the cobalt atom of the organocobalt complex. The bioactive agent is released from the bioconjugate by the cleavage of the covalent bond between the bioactive agent and the cobalt atom in the organocobalt complex. The cleavage may occur as a result of normal displacement by cellular nucleophiles or enzymatic action, but is preferably caused to occur selectively at a predetermined release site by application of an external signal. The external signal may be light or photoexcitation, i.e. photolysis, or it may be ultrasound, i.e. sonolysis. Further, if the photolysis takes places in the presence of a magnetic field surrounding the release site, the release of the bioactive agent into surrounding healthy tissue is minimized. Examples of targeting molecules include glucose, galactose, mannose, mannose 6phosphate, hormones (e.g., insulin, growth hormone, and the like), growth factors or cytokines (e.g., TGF-p, EGF, insulin-like growth factor, and the like), YEE(GalNAcAH)3 or derivatives, cobalamin, a-2 macroglobulins, asialoglycoprotein, albumin, texaphyrin, metallotexaphyrin, antibodies, antibody fragments (e.g., Fab), single-chain antibody variable region (scFv), transferrin, any vitamin and any coenzyme. The organocobalt complex is selected from the group consisting of an organo(pyridine)bis(dimethylglyoximato)cobalt, a corrinoid, or derivatives thereof.
Patients using topical corticosteroids should receive the following information and instructions:

  1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
  2. Patients should be advised not to use this medication for any disorder other than that for which it was prescribed.
  3. The treated skin area should not be bandaged or otherwise covered or wrapped in order to be occlusive unless the patient is directed to do so by the physician.
  4. Patients should report any signs of local adverse reactions, especially under occlusive dressing.
  5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a patient being treated in the diaper area, because these garments may constitute occlusive dressings.
  6. Do not use Flurandrenolide cream on the face, underarms, or groin areas unless directed by your physician.
  7. If no improvement is seen within 2 weeks, contact your physician.
  8. Do not use other corticosteroid-containing products while using Flurandrenolide cream without first consulting your physician.
BACKGROUND: No standard has been established regarding timing and choice of strategy for discontinuation of external ventricular drainage (EVD) in patients with aneurysmal subarachnoid haemorrhage (aSAH), and little is known about the importance of clinical variables. A proportion of the patients who initially pass their discontinuation attempt return with delayed hydrocephalus and the need of a permanent shunt. Early differentiation between patients who need a shunt and those who do not would facilitate care. We conducted a retrospective analysis on patients with aSAH and an EVD to search significant differences in treatment and clinical variables between patients who received a permanent shunt during initial hospitalization or after readmission, and those who never received a shunt.
METHODS: We included 183 patients with aSAH who received an EVD over a 4-year period between 2015 and 2018 and divided them into three groups: those who received a shunt during primary admission, those who were readmitted for delayed hydrocephalus and received a shunt, and those who never needed a shunt. Between these groups, we compared selected clinical variables as well as outcome at discharge and after 6 months. Additionally, we assessed the ability of a shunt dependency score (SDASH) to predict the need for permanent drainage in the patients.
RESULTS: Of 183 included patients, 108 (59%) ultimately received a ventriculoperitoneal (VP) shunt. Of these, 89 (82%) failed discontinuation during the primary admission and received a permanent shunt before discharge from the neurosurgical department. The remaining 19 (18%) were discharged after successful discontinuation, but subsequently developed delayed hydrocephalus and were admitted for shunt placement a median of 39 (range: 18-235) days after ictus. Ninety-four patients were discharged after successful discontinuation of the EVD, consisting of those who never developed the need for a permanent shunt and the 19 who were readmitted with delayed hydrocephalus, corresponding to a 20% (19/94) readmittance rate. Clinical variables such as drainage volume or discontinuation strategy did not differ across the three groups of patients. The SDASH score failed to provide any clinically useful information regarding prediction of shunt placement.
CONCLUSION: In this study, clinical variables including use of the predictive score SDASH predicted neither the overall need for nor the timing of shunt placement after aSAH. The homogeneous distribution of data between the three different groups renders strong independent clinical predictive factors unlikely. Thus, attempts to predict a permanent shunt requirement from these variables may be futile in these patients.
Every year children aged 0 to 19 years old are diagnosed with cancer around the world. For pediatric oncology patients, chemotherapy-related acute nausea and vomiting are among most common symptoms and has a bad influence on quality of life. When it cannot be prevented, it can cause serious medical problems. Continuous, repetitive and unavoidable vomiting affects patients' and their families' quality of life adversely, causing delay or even termination in chemotherapy treatment. It is a well-known fact that medical treatment is insufficient to control nausea and vomiting symptoms. Therefore, supportive care is needed besides medical treatment. One of the approaches mentioned is acupressure. Non-invasive stimulation of the P6 acupuncture point is a harmless and complementary approach to health. The point between flexor carpi radialis and palmaris longus, located at a three finger distance from the wrist crease, is named as "P6 Nei-Guan". This acupuncture point, placed on the pericardium channel, is generally used to harmonize stomach and relieve the vomiting. Acupressure is a way of stimulation applied on acupuncture points by finger, palm or acustimulation bands (sea-band, relief band) and can be used for children as well. Acupressure is defined as one of the complementary health approaches which nurses can apply. It is stated that this method, which is non-invasive, economical, easy to apply and reliable, has no side effect and patients can apply to themselves with a good guidance.

Chemotherapy-related nausea and vomiting are among the symptoms affecting children's quality of life and their adaptation to the treatment. There are limited amount of research intended to manage pediatric oncology patients' chemotherapy-related nausea and vomiting symptoms by using acupressure. It is thought that the research will provide significant contribution for literature, nursing practice and the quality of patient care since power of the study is high and it is the first study which efficiency of wrist-band, manuel acupressure and placebos is being compared for management of chemotherapy-related acute nausea and vomiting symptoms in pediatric oncology patients.
A flim-forming cream containing sericin and chitosan cream. Apply sericin and chitosan cream on the back area of healthy volunteers and cover with self-adhesive nonwoven fabric in induction phase I (72 hours), induction phase II (72 hours), and challenge phase (72 hours).
Rationale: Chronic sarcoidosis is a complex granulomatous disease with limited treatment options that can progress over time. Understanding the molecular pathways contributing to disease would aid in new therapeutic development. Objectives: To understand whether macrophages from patients with nonresolving chronic sarcoidosis are predisposed to macrophage aggregation and granuloma formation and whether modulation of the underlying molecular pathways influence sarcoidosis granuloma formation. Methods: Macrophages were cultivated in vitro from isolated peripheral blood CD14+ monocytes and evaluated for spontaneous aggregation. Transcriptomics analyses and phenotypic and drug inhibitory experiments were performed on these monocyte-derived macrophages. Human skin biopsies from patients with sarcoidosis and a myeloid Tsc2-specific sarcoidosis mouse model were analyzed for validatory experiments. Measurements and Main Results: Monocyte-derived macrophages from patients with chronic sarcoidosis spontaneously formed extensive granulomas in vitro compared with healthy control participants. Transcriptomic analyses separated healthy and sarcoidosis macrophages and identified an enrichment in lipid metabolic processes. In vitro patient granulomas, sarcoidosis mouse model granulomas, and those directly analyzed from lesional patient skin expressed an aberrant lipid metabolism profile and contained increased neutral lipids. Conversely, a combination of statins and cholesterol-reducing agents reduced granuloma formation both in vitro and in vivo in a sarcoidosis mouse model. Conclusions: Together, our findings show that altered lipid metabolism in sarcoidosis macrophages is associated with its predisposition to granuloma formation and suggest cholesterol-reducing therapies as a treatment option in patients.
PURPOSE: To describe a rare clinical finding of epiretinal membrane (ERM) and abnormal optic disc vascularisation in type 2A macular telangiectasia (MacTel).
CASE DESCRIPTION: A 52-year-old asymptomatic healthy male was examined in the retina clinic. In both eyes, corrected visual acuity was 20/20, N6. Anterior segment examination and intraocular pressure were both normal in both eyes.
RESULTS: The right eye's dilated fundus examination revealed loss of retinal transparency and superficial intraretinal crystals. A thick ERM extending from the optic disc to the macula obscured the details of the underlying perifoveal region in the left eye fundus. The diagnosis of bilateral type 2 MacTel was confirmed by confocal blue reflectance imaging, fluorescein angiography (FA), and macular optical coherence tomography (OCT). The left eye macular OCT scan also revealed a thick ERM without causing significant retinal traction. Furthermore, FA of the left eye revealed early hyperfluorescence with intense late leakage at the inferior aspect of the optic disc, giving the impression of abnormal optic disc vascularisation. No other cause for the disc vascularisation could be identified. OCT scan through the area with the optic disc leakage revealed a tuft of irregular hyperreflective tissue lying over the ERM. OCT angiography imaging confirmed the vascularity within the tuft of hyperreflective tissue over the ERM. Over a two-year period, no changes in clinical or imaging features were observed.
CONCLUSION: In type 2A MacTel eyes, ERM formation and abnormal disc vascularisation are uncommon findings. More histopathologic research is needed to characterise these membranes.
Thirty-six individuals divided three groups as mirror therapy, visual feedback, and control groups were included in the study for 15 sessions of treatment. All individuals received basic treatment as ultrasound, transcutaneous electrical nerve stimulation, cold pack, stretching exercises, glenohumeral range of motion exercises, scapulothoracic exercises. The mirror group bilateral exercised with an affected arm behind the mirror; visual feedback group bilateral exercised by seeing both arms in the mirror; control group bilateral exercised without a mirror for 10 minutes after every session. Pain severity was evaluated with the "Visual Analogue Scale (VAS)", ROM and proprioception were measured with a universal goniometer, and functional status was evaluated with "shoulder pain and disability index (SPADI)" and "Modified Constant Score". Evaluations were made before, day after the treatment and 4 weeks after the treatment by the same researcher. Data analysis was performed with SPSS.23.
Group A will perform plyometric training that includes squats, burpees, box jumps, tuck jumps, skaters hop, single-leg deadlift to jump. 10 reps of 3 sets with three sessions per week for 6 weeks.
The aim of this study is to compare the effectiveness and efficiency of immediate colposcopy (IC), repeat conventional cytology at 6 and 12 months (RC) and HPV triage (HPV) (QIAGEN-The digene HPV Test®) for the clinical management of women with ASC-US insured in healthcare management organizations (HMO) within the Colombian health security system. This study randomized 2,661 20-69 years old women with ASC-US, insured in HMOs in Medellin-Colombia to 3 arms: IC, RC and HPV. All women are scheduled for a visit at 2 years after recruitment that includes HPV-test/cytology and colposcopy either if HPV+ (RLU\>=1) or abnormal cytology (\>=ASC-US). This colposcopy is performed by a trained colposcopist and women are followed-up according to a well-defined algorithm. The fewer high-grade cervical neoplasia (CIN2+) rate at the end of following will determine the most effective arm. The most efficiency arm will be which reach the major effective with the minimum resource (cytologies, colposcopies and histologies) consumed. The resource consumed is being retrieved from the HMOs. This study also pretends to evaluate the acceptability of the HPV testing. This study will allow us to know if within the Colombian health security system, the HPV test will remain superior to repeating cytology and/or to immediate colposcopy as it has been demonstrated in randomized controlled trials carried out in outside settings.
The present invention discloses a kind of mutant KCNQI, i.e. S140G-KCNQ1, also discloses a method for screening inhibitor of myocardial KCNQ1 potassium ion channel by utilizing KCNQ1. It includes the following steps: (a). transferring expression rector for expressing (i) KCNQI and expression vector for expressing (ii) KCNE1 or expression vector for expressing KCNE2 into mammalian cell; (2). in the culture medium of transferred mammalian cell adding candidate substance and determining electric physiological potassium ion flow before and after addition of the candidate substance. If the electric physiological potasisum flow after the candidate substance added is reduced, it shows that the substance is the inhibitor of myocardial KCNQ1 potassium ion channel.
The invention discloses a polypeptide carrier used for improving targeting ability and transfection efficiency of a medicine/gene. The polypeptide carrier has a structure represented by a formula (I): TATp-Cys-LHRHp (I), wherein TATp is a TAT fragment of HIV, Cys is Cysteine, LHRHp is an analogue of luteinizing hormone releasing hormone LHRH. The polypeptide carrier provided by the invention carries a large amount of positive charges. The polypeptide carrier has good water-solubility and high targeting ability aiming at sexual hormone dependent tumor and liver cancer. The carrier can directlycarry negatively charged nucleic acid or medicine, and mediate the nucleic acid or medicine into cells. Also, the carrier can be used for modifying other gene or medicine carriers, such that tumor targeting abilities and transfection efficiency of the gene or medicine carriers can be improved. Therefore, a novel carrier is provided for gene/medicine delivering.
FIELD: biotechnology. SUBSTANCE: invention relates to methods of preparing biologically active compounds enriched with selenium based on microalgae biomass. The proposed method of preparing selenium-enriched biomass of Spirulina platensis involves inoculate preparing by preliminary cells adaptation in culturing for 7-10 passages on agarized media with low content of sulfur (5-10% of norm) in the presence of 15-30 mg/l of sodium selenite and the use of the prepared inoculate for production carrying out in nutrient media with the same selenium content as in preparing inoculate and with content of sulfur 15-30 mg/l (5-10% of norm). Invention allows to obtain biomass of Spirulina platensis with different enrichment with selenium as component of biologically active compounds by regulation of process of its accumulation at high growth and biomass accumulation rate that provides high output by biomass yield. Invention can be used in phytobiotechnology, microbiology, medicine, algology, food industry and agriculture. EFFECT: improved method of biomass preparing. 4 tbl
PCT No. PCT/FR96/01853 Sec. 371 Date May 20, 1998 Sec. 102(e) Date May 20, 1998 PCT Filed Nov. 22, 1996 PCT Pub. No. WO97/20002 PCT Pub. Date Jun. 5, 1997The present invention relates to a composition based on a sulphur compound, zinc and optionally a transparent oxide, to a process for its preparation and to its use as a dye pigment. The composition of the invention is characterized in that it comprises a support based on at least one sulphur compound, and a zinc compound, deposited on the support and obtained by reaction of a zinc precursor with aqueous ammonia and/or an ammonium salt. The composition may also comprise a layer based on at least one transparent oxide deposited at the surface of the support and/or fluorine atoms. It may be prepared in particular by a process in which the support, a zinc precursor, aqueous ammonia and/or an ammonium salt and, if necessary, a transparent oxide precursor and a fluorinating agent are placed in contact and the zinc compound is deposited on the support and, where appropriate, the transparent oxide is precipitated on the said support.